Trial Profile
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Dec 2023 Status changed from active, no longer recruiting to suspended.
- 01 Dec 2023 Following a planned safety analysis, the protocol was amended, and EPd induction was removed from the study schema. An additional 9 patients underwent induction off-study and were enrolled on trial for AHCT2 and EPd maintenance.
- 01 Dec 2023 Results published in the Transplantation and Cellular Therapy